NCT07078331View on ClinicalTrials.gov

Safety and Performance, and Dose, of OsteoAdapt DE in Localized Alveolar Ridge Augmentations

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 17, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Tooth Extraction Site HealingRidge AugmentationBone Graft
Interventions
DEVICE

OsteoAdapt DE (0.8 mg)

"Procedure of single tooth extraction and grafting along with related data collection:~Implanted OsteoAdapt DE bone graft (0.8 mg) by a trained and qualified study investigator per the IFU, IB and CIP guidelines"

DEVICE

OsteoAdapt DE (2.0 mg)

"Procedure of single tooth extraction and grafting along with related data collection:~Implanted OsteoAdapt DE bone graft (2.0 mg) by a trained and qualified study investigator per the IFU, IB and CIP guidelines"

DEVICE

Xenograft Bone Graft

"Procedure of single tooth extraction and grafting along with related data collection:~Implanted xenograft bone graft by a trained and qualified study investigator per the IFU, IB and CIP guidelines"

Trial Locations (3)

4941492

RECRUITING

Rabin Medical Center, Petah Tikva

5265601

RECRUITING

Sheba Medical Center, Tel Litwinsky

9112001

RECRUITING

Hadassah Medical Center, Jerusalem

All Listed Sponsors
lead

Theradaptive, Inc

INDUSTRY

NCT07078331 - Safety and Performance, and Dose, of OsteoAdapt DE in Localized Alveolar Ridge Augmentations | Biotech Hunter | Biotech Hunter